¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.
¼¼°è ÇÙÀÇÇÐ ¹æ»ç¼º ÀǾàǰ ½ÃÀåÀº 2025³â 77¾ï 2,000¸¸ ´Þ·¯, 2032³â¿¡´Â 138¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025-2032³â ¿¬Æò±Õ 8.7%ÀÇ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
º¸°í ¹üÀ§ |
º¸°í¼ »ó¼¼ ³»¿ë |
±âÁØ ¿¬µµ |
2024³â |
2025³â ½ÃÀå ±Ô¸ð |
77¾ï 2,000¸¸ ´Þ·¯ |
½ÇÀû µ¥ÀÌÅÍ |
2020-2024³â |
¿¹Ãø ±â°£ |
2025-2032³â |
¿¹Ãø ±â°£(2025-2032³â) CAGR |
8.70% |
2032³â ±Ý¾× ¿¹Ãø |
138¾ï 5,000¸¸ ´Þ·¯ |
±×¸². 2025³â Áö¿ªº° ÇÙÀÇÇÐ ¹æ»ç¼º ÀǾàǰ ½ÃÀå Á¡À¯À²(%)

¹æ»ç¼ºÀǾàǰÀº Áø´Ü°ú Ä¡·á ¸ñÀûÀ¸·Î ÇÙÀÇÇп¡¼ »ç¿ëµÇ´Â ¹æ»ç¼º ÀǾàǰÀÔ´Ï´Ù. ¹æ»ç¼ºÀǾàǰÀº ü³»¿¡ µµÀÔµÈ ¹æ»ç¼º ÃßÀûÀڷκÎÅÍ °¨¸¶¼± µîÀÇ ÇÙ ¹æ»ç¼±À» ¹æÃâÇÔÀ¸·Î½á ÀÇ·á¿ë ¿µ»óÁø´Ü ±â¼ú¿¡¼ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¹æ»ç¼ºÀǾàǰÀº ¹æ»ç¼º µ¿À§¿ø¼Ò¸¦ ´ÜŬ·Ð Ç×ü¿Í °°Àº »ý¸®È°¼º ÀǾàǰ ÈÇÕ¹°¿¡ °áÇÕ½ÃŲ °ÍÀ¸·Î Á¶Á÷, Àå±â, ¼¼Æ÷¸¦ ¼±ÅÃÀûÀ¸·Î Ç¥ÀûÈÇÏ¿© Á¶Á÷, Àå±â, ¼¼Æ÷¸¦ ¼±ÅÃÀûÀ¸·Î Ç¥ÀûÈÇÕ´Ï´Ù. ½ºÄµ Áß °¨¸¶ Ä«¸Þ¶ó¿ÍÀÇ »óÈ£ÀÛ¿ëÀ» ÅëÇØ ÀÇ»ç´Â ºñħ½ÀÀûÀ¸·Î ´ë»ç, »ý¸®Àû, ÇØºÎÇÐÀû ¼¼ºÎ »çÇ׿¡ ´ëÇÑ ±â´ÉÀû ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡, ¾Ï ¹× ½ÉÀå Áúȯ¿¡ Ãë¾àÇÑ ³ëÀÎ Áõ°¡, ¹æ»ç¼º ÃßÀûÀÚÀÇ ±â¼ú ¹ßÀüÀº ¹æ»ç¼ºÀǾàǰ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ ¼ö ÀÖ½À´Ï´Ù.
½ÃÀå ¿ªÇÐ
Áúº´ÀÇ Á¶±â Áø´Ü¿¡ ´ëÇÑ ¼ö¿äÀÇ ±ÞÁõ, À¯¸®ÇÑ »óȯ Á¤Ã¥, ÀÇ·áºñ ÁöÃâ Áõ°¡, ÇÙÀÇÇÐ Ä¡·áÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ÀÎ½Ä µîÀÌ ÇÙÀÇ·á¿ë ¹æ»ç¼ºÀǾàǰ ½ÃÀåÀ» °ßÀÎÇÒ °ÍÀÔ´Ï´Ù. ±×·¯³ª ¹æ»ç¼º ÃßÀûÀÚÀÇ ¹Ý°¨±â°¡ ª¾Æ ÇöÀå Á¦Á¶ ¼³ºñ°¡ ÇÊ¿äÇϰí, Àåºñ ¼³Ä¡ ¹× À¯Áöº¸¼ö ºñ¿ëÀÌ ³ô´Ù´Â Á¡Àº ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¬±¸°³¹ß Çù·ÂÀ» ÅëÇØ ½Å°æÇÐ, Èñ±ÍÁúȯ, °³ÀθÂÃãÇü ÀǷḦ À§ÇÑ »õ·Î¿î ¹æ»ç¼º ÃßÀûÀÚ¸¦ °³¹ßÇÏ´Â °ÍÀº ¼ºÀå ±âȸ¸¦ °¡Á®¿Ã ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀǾàǰ °³¹ß ¹× Ç¥Àû ¹æ»ç¼± Ä¡·áÀÇ ½ÅÈï ½ÃÀå °³Ã´µµ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ ¼ö ÀÖ½À´Ï´Ù.
º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡
- ¼¼°èÀÇ ÇÙÀÇÇÐ ºÐ¾ß ¹æ»ç¼ºÀǾàǰ(¹æ»ç¼ºÀǾàǰ) ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇßÀ¸¸ç, 2024³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯)¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR)¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
- ¶ÇÇÑ, ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¼öÀÍ ±âȸ¸¦ ÆÄ¾ÇÇϰí ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
- ¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ ÁÖ¿ä °íÂûÀ» Á¦°øÇÕ´Ï´Ù.
- º» º¸°í¼¿¡¼´Â ¼¼°è ÇÙÀÇÇÐ ¹æ»ç¼º ÀǾàǰ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏÀ» ±â¾÷ °³¿ä, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä Æ¯Â¡, À繫 ½ÇÀû, Àü·« µîÀÇ ÆÄ¶ó¹ÌÅ͸¦ ±âÁØÀ¸·Î Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
- ÀÌ º¸°í¼ÀÇ ÅëÂû·ÂÀ» ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
- ¼¼°è ÇÙÀÇÇÐ ¹æ»ç¼º ÀǾàǰ ½ÃÀå º¸°í¼´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷, À繫 ºÐ¼®°¡ µî ÀÌ »ê¾÷ÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
- ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è ÇÙÀÇÇÐ ¹æ»ç¼º ÀǾàǰ ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ½±°Ô ³»¸± ¼ö ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¸ñÀû°ú ÀüÁ¦Á¶°Ç
Á¦2Àå ½ÃÀå Àü¸Á
Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®
- ½ÃÀå ¿ªÇÐ
- ¼ºÀå ÃËÁø¿äÀÎ
- ¼ºÀå ¾ïÁ¦¿äÀÎ
- ±âȸ
- ¿µÇ⠺м®
- ½ÃÀå µ¿Çâ
- ±ÔÁ¦ ½Ã³ª¸®¿À
- Àμö¿Í Á¦ÈÞ ½Ã³ª¸®¿À
- ÀÚ±ÝÁ¶´Þ°ú ÅõÀÚ
- PEST ºÐ¼®
- PorterÀÇ Five Forces ºÐ¼®
Á¦4Àå ¼¼°èÀÇ ÇÙÀÇÇÐ ¹æ»ç¼º ÀǾàǰ ½ÃÀå - Äڷγª¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ
- ÀüüÀûÀÎ ¿µÇâ
- Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºê
- ½ÃÀå¿¡ ´ëÇÑ COVID-19ÀÇ ¿µÇâ
Á¦5Àå ¼¼°èÀÇ ÇÙÀÇÇÐ ¹æ»ç¼º ÀǾàǰ ½ÃÀå, Á¦Ç° À¯Çüº°, 2020-2032³â(10¾ï ´Þ·¯)
- ¼·Ð
- ÇÙÀÇ·á Áø´Ü
- SPECT ¹æ»ç¼º ÀǾàǰ
- PET ¹æ»ç¼º ÀǾàǰ
- ÇÙÀÇ·á Ä¡·á
Á¦6Àå ¼¼°èÀÇ ÇÙÀÇÇÐ ¹æ»ç¼º ÀǾàǰ ½ÃÀå, ¿ëµµº°, 2020-2032³â(10¾ï ´Þ·¯)
- ¼·Ð
- Á¾¾çÇÐ
- ½ÉÀ庴ÇÐ
- ½Å°æÇÐ
- ³»ºÐºñÇÐ
- ±âŸ
Á¦7Àå ¼¼°èÀÇ ÇÙÀÇÇÐ ¹æ»ç¼º ÀǾàǰ ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº°, 2020-2032³â(10¾ï ´Þ·¯)
- ¼·Ð
- º´¿ø
- ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
- Àü¹® Ŭ¸®´Ð
- Áø´Ü¼¾ÅÍ
- ±âŸ
Á¦8Àå ¼¼°èÀÇ ÇÙÀÇÇÐ ¹æ»ç¼º ÀǾàǰ ½ÃÀå, Áö¿ªº°, 2020-2032³â(10¾ï ´Þ·¯)
- ¼·Ð
- ºÏ¹Ì
- ¶óƾ¾Æ¸Þ¸®Ä«
- À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- 秵- ¾ÆÇÁ¸®Ä«
Á¦9Àå °æÀï ±¸µµ
- ±â¾÷ °³¿ä
- Progenics Pharmaceuticals, Inc.
- NorthStar Medical Radioisotopes LLC
- Curium Pharma
- Life Molecular Imaging
- Lantheus Holdings, Inc.
- Cardinal Health, Inc.
- General Electric Company
- Bracco SpA
- Bayer AG
- GE Healthcare
- Jubilant Pharmova Limited
- Eckert & Ziegler
- Mallinckrodt
- NTP Radioisotopes SOC Ltd.
- Telix Pharmaceuticals, Inc.
- Nordic Nanovector
- Y-mAbs Therapeutics, Inc.
- Siemens Healthineers AG
Á¦10Àå ¾Ö³Î¸®½ºÆ® Ãßõ »çÇ×
- À¶¼º°ú ¼èÅð
- Coherent Opportunity Map
Á¦11Àå Âü°í ¹®Çå°ú Á¶»ç ¹æ¹ý
LSH 25.04.01
Global Radiopharmaceuticals in Nuclear Medicine Market is estimated to be valued at USD 7.72 Bn in 2025 and is expected to reach USD 13.85 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.7% from 2025 to 2032.
Report Coverage |
Report Details |
Base Year: |
2024 |
Market Size in 2025: |
USD 7.72 Bn |
Historical Data for: |
2020 To 2024 |
Forecast Period: |
2025 To 2032 |
Forecast Period 2025 to 2032 CAGR: |
8.70% |
2032 Value Projection: |
USD 13.85 Bn |
Figure. Radiopharmaceuticals In Nuclear Medicine Market Share (%), By Region 2025

Radiopharmaceuticals are radioactive drugs used in nuclear medicine for both diagnostics and therapeutics purposes. These play a crucial role in medical imaging techniques through emission of nuclear radiation such as gamma rays from radioactive tracers introduced into the body. Radiopharmaceuticals consist of radioactive isotopes bonded to bioactive pharmaceutical compounds like monoclonal antibodies to selectively target tissues, organs or cells. On interaction with gamma cameras during scans, these help physicians gain functional insights into metabolic, physiological and anatomical details non-invasively. Rising prevalence of chronic diseases, growing geriatric population susceptible to cancer and cardiac ailments and technological advancements in radiotracers can drive the growth of radiopharmaceuticals market.
Market Dynamics:
Surging demand for early disease diagnosis, favorable reimbursement policies, increasing healthcare expenditure, and awareness about benefits of nuclear medicine procedures can drive the radiopharmaceuticals in nuclear medicine market. However, short half-lives of radiotracers requiring on-site production facilities and high installation and maintenance costs of equipment can hamper the market growth. Developing new radiotracers for neurology, rare diseases and personalized medicine through R&D collaborations can offer growth opportunities. Emerging applications in drug development and targeted radiotherapy can also drive the market growth.
Key Features of the Study:
- This report provides in-depth analysis of the global radiopharmaceuticals in nuclear medicine market, and provides market size (USD billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global radiopharmaceuticals in nuclear medicine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include GE Healthcare, Bracco Imaging S.p.A., Lantheus Medical Imaging Inc., Bayer AG, Novartis AG (Advanced Accelerator Applications), Nordion Inc., and Jubilant DraxImage Inc. dba Jubilant Radiopharma
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global radiopharmaceuticals in nuclear medicine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global radiopharmaceuticals in nuclear medicine market
Detailed Segmentation-
- By Product Type
- Diagnostic Nuclear Medicine
- SPECT Radiopharmaceuticals
- PET Radiopharmaceuticals
- Therapeutic Nuclear Medicine
- By Application
- Oncology
- Cardiology
- Neurology
- Endocrinology
- Others
- By End User
- Hospitals
- Ambulatory Surgical Centers
- Specialty Clinics
- Diagnostic Centers
- Others
- By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- Progenics Pharmaceuticals, Inc.
- NorthStar Medical Radioisotopes LLC
- Curium Pharma
- Life Molecular Imaging
- Lantheus Holdings, Inc.
- Cardinal Health, Inc.
- General Electric Company
- Bracco S.p.A.
- Bayer AG
- GE Healthcare
- Jubilant Pharmova Limited
- Eckert & Ziegler
- Mallinckrodt
- NTP Radioisotopes SOC Ltd.
- Telix Pharmaceuticals, Inc.
- Nordic Nanovector
- Y-mAbs Therapeutics, Inc.
- Siemens Healthineers AG
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Product Type
- Market Snapshot, By Application
- Market Snapshot, By End User
- Market Snapshot, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Regulatory Scenario
- Acquisitions and Partnerships Scenario
- Funding and Investments
- PEST Analysis
- Porter's Analysis
4. Global Radiopharmaceuticals in Nuclear Medicine Market- Impact of Coronavirus (COVID-19) Pandemic
- Overall Impact
- Government Initiatives
- COVID-19 Impact on the Market
5. Global Radiopharmaceuticals in Nuclear Medicine Market, By Product Type, 2020 - 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Diagnostic Nuclear Medicine
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- SPECT Radiopharmaceuticals
- PET Radiopharmaceuticals
- Therapeutic Nuclear Medicine
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Radiopharmaceuticals in Nuclear Medicine Market, By Application, 2020 - 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oncology
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Cardiology
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Neurology
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Endocrinology
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Radiopharmaceuticals in Nuclear Medicine Market, By End User, 2020 - 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Ambulatory Surgical Centers
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Specialty Clinics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Diagnostic Centers
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Radiopharmaceuticals in Nuclear Medicine Market, By Region, 2020 - 2032, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021-2032
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Company Profiles
- Progenics Pharmaceuticals, Inc.
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- NorthStar Medical Radioisotopes LLC
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Curium Pharma
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Life Molecular Imaging
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Lantheus Holdings, Inc.
- Cardinal Health, Inc.
- General Electric Company
- Bracco S.p.A.
- Bayer AG
- GE Healthcare
- Jubilant Pharmova Limited
- Eckert & Ziegler
- Mallinckrodt
- NTP Radioisotopes SOC Ltd.
- Telix Pharmaceuticals, Inc.
- Nordic Nanovector
- Y-mAbs Therapeutics, Inc.
- Siemens Healthineers AG
10. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us and Sales Contact